AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback